Journal of Clinical Endocrinology & Metabolism, Vol 56, 332-339, Copyright © 1983 by Endocrine Society

ARTICLES

Metabolic and blood pressure responses to hydrocortisone in the syndrome of apparent mineralocorticoid excess

SE Oberfield, LS Levine, RM Carey, F Greig, S Ulick and MI New

A syndrome of low renin hypertension in childhood with apparent mineralocorticoid excess associated with a defect in the peripheral metabolism of cortisol has been described previously in 2 patients. In these patients, decreased secretion rates of glucocorticoids, mineralocorticoids, and sex steroids have been demonstrated. In a 10(10/12)-yr-old girl with this disorder, continuous iv administration of hydrocortisone in doses of 5, 10, 15, and 20 mg/day resulted in an increase in blood pressure and a decrease in serum potassium concentration. The addition of spironolactone during the continued administration of 20 mg/day hydrocortisone did not result in a decrease in blood pressure. Withdrawal of hydrocortisone and continued administration of spironolactone alone resulted in a decrease in blood pressure, a rise in serum potassium concentration, and a fall in serum sodium concentrations. These studies suggest that an abnormality in cortisol action or metabolism causing cortisol to behave as a potent mineralocorticoid may account for this syndrome of apparent mineralocorticoid excess.

This article has been cited by other articles:

				A. Bhargava, M. J. Fullerton, K. Myles, T. M. Purdy, J. W. Funder, D. Pearce, and T. J. Cole The Serum- and Glucocorticoid-Induced Kinase Is a Physiological Mediator of Aldosterone Action Endocrinology, April 1, 2001; 142(4): 1587 - 1594. [Abstract] [Full Text]

				J. A. Whitworth, G. J. Mangos, and J. J. Kelly Cushing, Cortisol, and Cardiovascular Disease Hypertension, November 1, 2000; 36(5): 912 - 916. [Abstract] [Full Text] [PDF]

				M. I. New and R. C. Wilson Steroid disorders in children: Congenital adrenal hyperplasia and apparent mineralocorticoid excess PNAS, October 26, 1999; 96(22): 12790 - 12797. [Abstract] [Full Text] [PDF]

				S. Dave-Sharma, R. C. Wilson, M. D. Harbison, R. Newfield, M. R. Azar, Z. S. Krozowski, J. W. Funder, C. H. L. Shackleton, H. L. Bradlow, J.-Q. Wei, et al. Examination of Genotype and Phenotype Relationships in 14 Patients with Apparent Mineralocorticoid Excess J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2244 - 2254. [Abstract] [Full Text]

				D. J. Morris, S. A. Latif, M. D. Rokaw, C. O. Watlington, and J. P. Johnson A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy Am J Physiol Cell Physiol, May 1, 1998; 274(5): C1245 - C1252. [Abstract] [Full Text] [PDF]

				S. H.M. van Uum, A. R.M.M. Hermus, P. Smits, T. Thien, and J. W.M. Lenders The role of 11{beta}-hydroxysteroid dehydrogenase in the pathogenesis of hypertension Cardiovasc Res, April 1, 1998; 38(1): 16 - 24. [Abstract] [Full Text] [PDF]

				P. C. White, T. Mune, and A. K. Agarwal 11{beta}-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess Endocr. Rev., February 1, 1997; 18(1): 135 - 156. [Abstract] [Full Text]

				Y. H. Lo, M. F. Sheff, S. A. Latif, C. Ribeiro, H. Silver, A. S. Brem, and D. J. Morris Kidney 11{beta}-HSD2 Is Inhibited by Glycyrrhetinic Acid-Like Factors in Human Urine Hypertension, January 1, 1997; 29(1): 500 - 505. [Abstract] [Full Text] [PDF]

				P. C. White Inherited Forms of Mineralocorticoid Hypertension Hypertension, December 1, 1996; 28(6): 927 - 936. [Abstract] [Full Text]

				G. W. Souness and D. J. Morris 11{alpha}- and 11ß-Hydroxyprogesterone, Potent Inhibitors of 11ß-Hydroxysteroid Dehydrogenase, Possess Hypertensinogenic Activity in the Rat Hypertension, March 1, 1996; 27(3): 421 - 425. [Abstract] [Full Text]

				B. A. Dickson and R. C. Franks Aldosterone-producing Adenoma Presenting with Hypokalemic Myopathy: Case Report and Review Clinical Pediatrics, July 1, 1988; 27(7): 344 - 347. [Abstract] [PDF]